Based on these previous publications in which SPLUNC1 activity has been defined, one can surmise that the clinical implications for individuals with low CC16 levels, such as asthma, COPD, and cystic fibrosis patients (10–12, 14), is that they may also have decreased pulmonary SPLUNC1 levels and therefore a myriad of SPLUNC1-deficiency related respiratory symptoms. Here, BPIFA1 is linked to asthma.